G7 Dual Mobility With Vivacit-E or Longevity PMCF

Prior treatment

• Patient has any concomitant disease which is likely to jeopardize the functioning or success of the implant
• The patient is in a vulnerable population group such as:
  • a prisoner
  • a known alcohol or drug abuser
  • mentally incompetent or unable to understand what participation in this study entails

Other illness

• Patient is septic, has an active infection or has osteomyelitis at the affected joint
• Patient has metabolic disorder(s) which may impair bone formation
• Patient has distant foci of infections which may spread to the implant site
• Patient has vascular insufficiency, muscular atrophy at the implant site or neuromuscular disease which are likely to jeopardize the outcome of the surgery.

Other

• Patient has significant osteoporosis as defined by treating surgeon
• Patient has osteomalacia
• Patient has rapid joint destruction, marked bone loss or bone resorption apparent on pre-operative radiographs
• Patient underwent contralateral THA within 3 months of planned index procedure or has a contralateral THA planned within 3 months of the index procedure
• Patient is undergoing simultaneous bilateral THA
• Patient is known to be pregnant

• Patient is 18 to 80 years of age, inclusive
• Patient is skeletally mature
• Patient qualifies for (total) hip arthroplasty based on physical exam and medical history including at least one of the following:
  • Non-inflammatory degenerative joint disease, including osteoarthritis and avascular necrosis
  • Rheumatoid arthritis
  • Dislocation risks
  • Correction of functional deformity
  • Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
  • Revision procedures where other treatment or devices have failed.
• Patient is willing and able to complete scheduled follow-up evaluations as described in the protocol and Informed Consent
• Patient, or the patient's legally authorized representative (LAR), has participated in the Informed Consent process and is willing and able to sign an IRB/EC approved Informed Consent